Ozempic sales surge could continue into 2024, researchers say
Novo Nordisk’s diabetes treatment Ozempic could be the drug industry’s second-highest seller in 2024, according to Evaluate’s latest forecast, as analysts and physicians signal the beginning of a new era for weight management.
The forecast expects Ozempic to generate nearly $12.4 billion in 2023. If the market research firm’s predictions are correct, the GLP-1 treatment will rank fifth among this year’s top-selling drugs after not even entering the top 10 in 2022. Novo’s obesity and diabetes care sales have skyrocketed in recent months, up 39% in Q2 2023 compared to Q2 2022, according to the company’s latest earnings report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.